GeneralConnection.com ➔ Dictionary
Dictionary Search

factor ix

Synonyms

Noun

1. Christmas factor

2. factor IX, coagulation factor, clotting factor

Usage
Factor IX-Padua AAV gene therapy in hemophilia B: phases 1/2 and 3 trials - Nature
Single-Dose Gene Therapy Shows Promising Safety, Efficacy, and Patient-Reported Outcomes in Hemophilia B - Docwire News
Final Analysis of a Study of Etranacogene Dezaparvovec for Hemophilia B - The New England Journal of Medicine
Advances in hemophilia, sickle cell disease, and thalassemia - Penn Medicine
AAV gene therapy shows durable benefit in hemophilia B - 2 Minute Medicine
Systemic lupus erythematosus caused acquired hemophilia B without evidence of factor IX inhibitors - Wiley Online Library
EAHAD 2026: Nine-Year Outcomes of Gene Therapy - EMJ
Tailored collagen binding of albumin-fused hyperactive coagulation factor IX dictates in vivo distribution and functional properties - Nature
Hemophilia B Gene Therapy Continues to Reduce Bleeding - Medscape
ASH: CSL proves efficacy of hemophilia B gene therapy Hemgenix holds up after 5 years - Fierce Pharma
Explainer 2025 Why Is Hemophilia B Called Christmas Disease - Global Biotechnology Company
Biogen Idec to Present Data from Hematology Programs, Including ELOCTATE™ and ALPROLIX® at ASH Annual Meeting - Biogen
Exploring gene editing as a potential therapeutic strategy for hemophilia - Frontiers
Gene Therapy Maintains Efficacy in Hemophilia B Out to 5 Years - MedPage Today
First subject dosed in Be Biopharma’s trial of haemophilia B therapy - Clinical Trials Arena
How Gene Therapy Is Transforming Hemophilia B Treatment - Docwire News
Gene Therapy Supply Runs Out, Company Warns of Treatment Delays - MedPage Today
Successful management with regular factor IX replacement during pregnancy in a hemophilia B carrier: A case report - Wiley
Sustained Clinical Benefit of AAV Gene Therapy in Severe Hemophilia B - The New England Journal of Medicine
How durable is gene therapy for haemophilia B? - Nature
One dose of gene therapy gives years of relief from blood disorder - Nature
Hemophilia B gene therapy demonstrates long-term success - St. Jude Children's Research Hospital
Haemophilia A vs B: Which is more severe? Here’s what sets them apart - TheHealthSite
Hemophilia B Gene Therapy Sustains Efficacy Over a Decade Later - MedPage Today
Gene Therapy Cuts Bleeding and Medicine for Hemophilia B Patients for Over a Decade - Managed Healthcare Executive
Hemophilia B Gene Therapy with a High-Specific-Activity Factor IX Variant - The New England Journal of Medicine
Use of anti-haemophilia medicine suspended across Punjab after reports of adverse reactions - The Tribune
Coagulation factor IX analysis in bioreactor cell culture supernatant predicts quality of the purified product - Nature
Long-Term Safety and Efficacy of Factor IX Gene Therapy in Hemophilia B - The New England Journal of Medicine
Phase 3 Study of Recombinant Factor IX Fc Fusion Protein in Hemophilia B - The New England Journal of Medicine
World Haemophilia Day on April 17 - Manorama Yearbook
The National “New Methods” Decision Forum in Norway recommends CSL’s gene therapy HEMGENIX® for adults with severe or moderately severe haemophilia B without a history of Factor IX inhibitors - Mynewsdesk
Systemic delivery of factor IX messenger RNA for protein replacement therapy - PNAS
Gene Therapy with Etranacogene Dezaparvovec for Hemophilia B - The New England Journal of Medicine
Hemophilia A Market Outlook - Grand View Research
Effects of codon optimization on coagulation factor IX translation and structure: Implications for protein and gene therapies - Nature
Hemlibra: Dosage, cost, side effects, and more - Medical News Today
Haemophilia gene therapy patients thriving over a decade after treatment | UCL News - UCL - UCL | University College London
X-Linked Thrombophilia with a Mutant Factor IX (Factor IX Padua) - The New England Journal of Medicine
Multiyear Follow-up Study Shows Positive Results for Hemophilia B Gene Therapy - Managed Healthcare Executive
Plasma factor IX: The tip of the iceberg? - Sidonio - 2021 - Haemophilia - Wiley Online Library
Data Published in the New England Journal of Medicine Confirm the Long-term Durability and Safety of HEMGENIX® (etranacogene dezaparvovec) Over Five Years - Mynewsdesk
A novel snake venom C-type lectin-like protein modulates blood coagulation by targeting von Willebrand factor and coagulation factor IX - Nature
Genome wide CRISPR/Cas9 screen identifies the coagulation factor IX (F9) as a regulator of senescence - Nature
This gene therapy costs $5 million a dose. Is it worth the price? - SMH.com.au
New Recombinant Factor IX Leads to Significant Cost Savings in Hemophilia B - AJMC
Etranacogene Dezaparvovec Displays Superiority to Factor IX Prophylaxis for Hemophilia B in HOPE-B Trial Data - CGTLive®
First gene therapy to treat haemophilia B - European Medicines Agency (EMA)
Hemophilia B: Post-Beqvez, What’s Next for Gene Therapy? - Medscape
HTC Population Profile Patient Characteristics - Centers for Disease Control and Prevention | CDC (.gov)
NICE recommends Pfizer’s new once-weekly treatment for haemophilia B on NHS - Pharmafile
Novel Insights and New Developments Regarding Coagulation Revealed by Studies of the Anti-Factor IXa (Activated Factor IX)/Factor X Bispecific Antibody, Emicizumab - American Heart Association Journals
PBPK modeling of recombinant factor IX Fc fusion protein (rFIXFc) and rFIX to characterize the binding to type 4 collagen in the extravascular space - Wiley
Plasma Kallikrein Contributes to Coagulation in the Absence of Factor XI by Activating Factor IX - American Heart Association Journals
Anticoagulant Protein S Targets the Factor IXa Heparin-Binding Exosite to Prevent Thrombosis - American Heart Association Journals
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial - Applied Clinical Trials Online
Phase 1–2 Trial of AAVS3 Gene Therapy in Patients with Hemophilia B - The New England Journal of Medicine
Managing surgery in hemophilia with recombinant factor VIII Fc and factor IX Fc: Data on safety and effectiveness from phase 3 pivotal studies - Wiley Online Library
Recombinant factor IX Fc fusion protein in children with haemophilia B (Kids B-LONG): results from a multicentre, non-randomised phase 3 study - The Lancet
Etranacogene dezaparvovec gene therapy reduces bleeding in severe hemophilia B - 2 Minute Medicine
Association Between Hepatic Triglyceride Content and Coagulation Factors: - American Heart Association Journals
UC San Diego Health First to Offer Novel Gene Therapy for Hemophilia B - UC San Diego Health
Factor Levels Lower Than 50% Associated With Postpartum Complications in Patients With Hemophilia - Hematology Advisor
Crystal structure of an anticoagulant protein in complex with the Gla domain of factor X - PNAS
Kallikrein directly interacts with and activates Factor IX, resulting in thrombin generation and fibrin formation independent of Factor XI - PNAS
Pfizer: Beqvez Gene Therapy Decreases Bleeding Rates in Hemophilia B Patients - 2 Minute Medicine
A coagulation factor moonlights in the heart - Science | AAAS
Gene therapy fails to induce sustained factor IX activity for patients with hemophilia B - Healio
Multiyear Factor VIII Expression after AAV Gene Transfer for Hemophilia A - The New England Journal of Medicine
FDA Accepts Biogen Idec’s Biologics License Application for First Long-Lasting Factor IX Therapy for Hemophilia B - Biogen
Factor IX Deficiency and Prolonged Bleeding Time - The New England Journal of Medicine
SRY-Box transcription factor 9 triggers YAP nuclear entry via direct interaction in tumors - Nature
Glucocorticoids increase adiposity by stimulating Krüppel-like factor 9 expression in macrophages - Nature
Coagulation factors VII, IX and X are effective antibacterial proteins against drug-resistant Gram-negative bacteria - Nature
Intellia opts out of hemophilia B gene editing work with Regeneron - Fierce Biotech
Nanobodies against factor XI apple 3 domain inhibit binding of factor IX and reveal a novel binding site for high molecular weight kininogen - Wiley Online Library
Hemophilia B Gene Therapy Produces Durable Response for 90% of Participants - AJMC
Gene Therapy for Hemophilia B Significantly Outperforms Factor IX Prophylaxis - MedPage Today
Real-world outcomes with recombinant factor IX Fc fusion protein (rFIXFc) prophylaxis: Longitudinal follow-up in a national adult cohort - Wiley Online Library
Translational Potential of Immune Tolerance Induction by AAV Liver-Directed Factor VIII Gene Therapy for Hemophilia A - Frontiers
Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response - Nature
VisualAbstract: Gene Therapy with Fidanacogene Elaparvovec in Adults with Hemophilia B is Superior to Prophylaxis - 2 Minute Medicine
Growth differentiation factor-9 stimulates progesterone synthesis in granulosa cells via a prostaglandin E - PNAS
Effective Blood Clotting Treatment:Pharmacogenomic Studies of ADAMTS13 - fda.gov
A genetic analysis of 23 Chinese patients with hemophilia B - Nature
Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors - The New England Journal of Medicine
Personal Story: Carrie - Centers for Disease Control and Prevention | CDC (.gov)
Hemophilia Gene Therapies Show Effectiveness and Safety in NEJM Reports - Inside Precision Medicine
Safety and activity of an engineered, liver-tropic adeno-associated virus vector expressing a hyperactive Padua factor IX administered with prophylactic glucocorticoids in patients with haemophilia B: a single-centre, single-arm, phase 1, pilot trial - The Lancet
Hemophilia therapy: the future has begun - Haematologica
Expert Q&A: The Current State of Gene Therapy for Hemophilia - Hematology Advisor
Fusion of engineered albumin with factor IX Padua extends half-life and improves coagulant activity - Wiley Online Library
Fibroblast Growth Factor 9 is expressed by activated hepatic stellate cells and promotes progression of hepatocellular carcinoma - Nature
Single-dose gene therapy is potentially life-changing for adults with hemophilia B - Penn Medicine
New Biogen Hemophilia Data At ISTH Congress to Highlight Extension Study Outcomes and Pediatric Use - Biogen
Is Hemophilia a Nosologic Entity? - ScienceDirect.com
The Prevalence of Proteolytic Antibodies against Factor VIII in Hemophilia A - The New England Journal of Medicine
Hemophilia B Gene Therapy Shows Promise in Clinical Trial - Genetic Engineering and Biotechnology News
UK Approves Marstacimab for Severe Haemophilia A or B - Medscape
Factor IX Deficiency and Prolonged Bleeding Time - The New England Journal of Medicine
Foreign Language Equivalents
Foreign Language Equivalents of 'factor ix'
Language Equivalent   Language Equivalent
French    Spanish
Misspellings - Typos
faxtor ix,   actor ix,   facor ix,   factor x,   ffactor ix,   factor ux,   facctor ix,   fator ix,   favtor ix,   facter ix,   factor ox,   fatcor ix,   factor xi,   factir ix,   dactor ix,   fctor ix,   afctor ix,   factorr ix,   factor iix,   factor ic,   facto ix,   factor ix,   factor i,   factor iz,   faactor ix,   fsctor ix,   factr ix,   factor ixx,   fcator ix,   facto rix,   facttor ix,   factpr ix,   factorix,   factoe ix,   facror ix,   factoor ix,   factro ix,   factori x,   factot ix,   gactor ix,   facotr ix,   facyor ix
Words Starting with Letter - 'A'
a a battery a billion
a bit a bit much a capella singing
a cappella singing a couple of a few
a fortiori a good deal a great deal
a horizon a hundred a hundred and one
a hundred thousand a hundred times a kempis
a la carte a la mode a level
a little a lot a million
Go to Page 1              Go to Page 2 »   
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z